Anne Peters, MD
Endocrinology, Diabetes & Metabolism · Beverly Hills, CANPI 1376572784
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $85,861 of the $121,362 with a category attached, or 70.7%. 26 manufacturers reported payments, led by Novo Nordisk at 25.4% of the total. Reporting peaked in 2019 at $44,486 and has fallen 93.0% since, to $3,130 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $597.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$31K
- Abbott$19K
- Eli Lilly$19K
- Mannkind Corporation$15K
- Boehringer Ingelheim$9K
- Zealand Pharma US, Inc.$9K
- plus $19K from 20 others
Across 56 payments — averaging $7962.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$293K
- Insulet Corporation$141K
- Sanofi-aventis U.S. LLC$7K
- Abbott$5K
What the payments were for
- Consulting fees$85,86171%
- Speaking & faculty fees$26,99622%
- Travel & lodging$4,1743%
- Food & beverage$4,2894%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 32 | $30,853 |
| Abbott | 17 | $19,378 |
| Eli Lilly | 16 | $18,985 |
| Mannkind Corporation | 20 | $15,062 |
| Boehringer Ingelheim | 12 | $9,457 |
| Zealand Pharma US, Inc. | 7 | $8,656 |
| Vertex | 3 | $7,578 |
| Tandem Diabetes Care, Inc. | 5 | $2,601 |
| Medtronic | 3 | $2,500 |
| Merck | 2 | $2,125 |
| Sanofi US Services Inc. | 2 | $2,090 |
| Insulet Corporation | 48 | $637 |
| Companion Medical, Inc. | 5 | $577 |
| Dexcom, Inc. | 2 | $286 |
| Sequel Med Tech, LLC | 1 | $90 |
| Lilly USA, LLC | 7 | $87 |
| Sanofi-aventis U.S. LLC | 4 | $75 |
| AstraZeneca | 3 | $58 |
| Johnson & Johnson | 3 | $57 |
| Novartis | 3 | $56 |
| AbbVie | 2 | $50 |
| Sanofi Pasteur Inc. | 2 | $33 |
| Cipher Pharmaceuticals US LLC | 1 | $23 |
| Antares Pharma, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Celltrion, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$14,797
- FreeStyle Libre Pro$13,613
- JARDIANCE$9,182
- ZEGALOGUE$8,581
- FreeStyle Libre$3,955
- t:slim X2 insulin pump$2,500
- SOTAGLIFLOZIN$2,090
- InPen$2,000
- Minimed 770G System$1,000
- DEXCOM G6 TRANSMITTER$158
- DEXCOM CGM$128
How this compares
$121,362 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 297 | $382,948 |
| MounjaroTirzepatide | 189 | $201,626 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 105 | $142,007 |
| JardianceEmpagliflozin | 101 | $102,171 |
| JanuviaSitagliptin Phosphate | 53 | $65,259 |
| Tresiba Flextouch U-100Insulin Degludec | 95 | $60,529 |
| HumalogInsulin Lispro | 110 | $34,107 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 25 | $33,551 |
| TradjentaLinagliptin | 44 | $28,178 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $22,332 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 16 | $21,756 |
| FarxigaDapagliflozin Propanediol | 28 | $19,786 |
| AfrezzaInsulin Regular, Human | 24 | $14,494 |
| TrulicityDulaglutide | 14 | $13,600 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 85 | $11,589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $30,853 | $426,232346 claims |
| Lilly USA, LLCMounjaro, Humalog, Trulicity | $87 | $249,333313 claims |
| Boehringer IngelheimJardiance, Tradjenta | $9,457 | $130,349145 claims |
| MerckJanuvia | $2,125 | $65,25953 claims |
| AstraZenecaFarxiga | $58 | $19,78628 claims |
| Mannkind CorporationAfrezza | $15,062 | $14,49424 claims |
| AbbVieSynthroid | $50 | $4,91068 claims |
| Sanofi-aventis U.S. LLCLantus | $75 | $1,92124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Beverly Hills
- Reza NazemiBeverly Hills$97K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.